Why the study?
Does candesartan reduce mortality and morbidity in heart failure patients?
Does candesartan reduce mortality and morbidity in heart failure patients?
Candesartan is an effective treatment for reducing mortality and morbidity across the spectrum of heart failure patients, regardless of ejection fraction or concurrent ACE inhibitor use.
Supports candesartan benefit in HFrEF; leaves open efficacy in preserved EF pending adequate event rates.
Candesartan is a long-acting angiotensin receptor antagonist that is well absorbed from the gastrointestinal tract, with insurmountable receptor binding abilities. Recent studies have shown candesartan to be an effective therapy for heart failure patients, producing a significant reduction in mortality and morbidity. Importantly, studies have demonstrated that candesartan is effective in heart failure patients who are intolerant to angiotensin-converting enzyme inhibitors, in patients already receiving angiotensin-converting enzyme inhibitors and for heart failure patients with preserved systolic function. The primary end point in the latter group failed to achieve statistical significance due to the small number of events. This paper will review the data supporting the use of candesartan to treat all heart failure patients, regardless of their ejection fraction.
No takes yet. Share an insight, caveat, or question.
Robert S. McKelvie (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: